Ontology highlight
ABSTRACT:
SUBMITTER: Vanella V
PROVIDER: S-EPMC5739559 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature
Vanella Vito V Festino Lucia L Strudel Martina M Simeone Ester E Grimaldi Antonio M AM Ascierto Paolo A PA
Oncoimmunology 20170921 1
Checkpoint inhibitors have improved survival for patients with melanoma, non-small-cell lung cancer (NSCLC), bladder, head and neck and other cancers. Antibodies against PD-L1, including atezolizumab, avelumab and durvalumab, are also being developed and have been approved for various cancers. Compared with anti-CTLA-4 drugs, studies with anti-PD-1/PD-L1 agents have suggested higher response rates and improved survival. Targeting PD-L1 rather than PD-1 may also theoretically offer further benefi ...[more]